Floatz logo

Durvalumab

Locally Advanced Pancreatic Carcinoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

103 Active assets in the Locally Advanced Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Capecitabine
Zhejiang University
Phase 2BB
Gdc-0449
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Durvalumab is also rated in:

primary peritoneal carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
urothelial carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →